Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative
Author(s):
Cuppens, T.; Annibali, D.; Coosemans, A.; Trovik, J.; Haar, N. ter; Colas, E.; Garcia-Jimenez, A.; Vijver, K. van de; Kruitwagen, R.P.M.; Brinkhuis, M.; Zikan, M.; Dundr, P.; Huvila, J.; Carpen, O.; Haybaeck, J.; Moinfar, F.; Salvesen, H.B.; Stukan, M.; Mestdagh, C.; Zweemer, R.P.; Massuger, L.F.; Mallmann, M.R.; Wardelmann, E.; Mints, M.; Verbist, G.; Thomas, D.; Gomme, E.; Hermans, E.; Moerman, P.; Bosse, T.; Amant, F.
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-03-01
Language
English
Is part of
Clinical Cancer Research (2017), Vol. 23, no. 5, p. 1274-1285
